Core Insights - The brain-computer interface (BCI) technology is at a critical industrial turning point, transitioning from academic exploration to commercial application, driven by policy and demand [1][4] - The medical field is the primary battlefield for BCI applications, accounting for 56% of the market, while non-medical sectors such as consumer, industrial, and education represent a combined 44%, indicating strong expansion potential [2][3] Industry Overview - BCI technology enables direct communication between the brain and external devices, facilitating bidirectional interaction from neural signals to control commands. The technology is categorized into invasive, semi-invasive, and non-invasive methods, with no absolute superiority among them; suitability depends on specific applications [1][3] - The global BCI market is projected to grow from $1.98 billion in 2023 to $7.63 billion by 2029, with China's market expected to reach 1.73 billion yuan in 2023, increasing its global share to 12.5% [2] Development Challenges - The BCI industry faces several challenges, including balancing high-throughput, high signal-to-noise ratio signal acquisition with long-term biocompatibility, and the need for breakthroughs in decoding algorithms and adaptive control precision [3] - Clinical challenges include the need for large-scale trials to verify the long-term safety and efficacy of invasive products, as well as the maturity of indication definitions, surgical standardization, and postoperative management systems [3] Global and Domestic Progress - The global BCI industry ecosystem is rapidly developing, with leading companies like Neuralink and Synchron innovating in high-throughput flexible implants and vascular interventions to enhance brain signal acquisition and interaction systems [4] - In China, significant progress has been made in system integration and application implementation, with a diverse enterprise matrix represented by companies such as Strong Brain Technology (non-invasive), Borui Kang (semi-invasive), and Xinwei Medical (interventional) [4] Relevant Companies - Key players in the primary market include Strong Brain Technology, Borui Kang, Ladder Medical, and others; in the secondary market, upstream companies like Maipu Medical and Meihao Medical, midstream companies like Xinwei Medical-B and Xiangyu Medical, and downstream companies like Sanbo Neuroscience are notable [5]

近日，国家药监局批准《采用脑机接口技术的医疗器械 范式设计与应用规范 运动功能重建》《采用脑 机接口技术的医疗器械 侵入式设备 可靠性验证方法》等2项医疗器械行业标准制修订项目立项，为采用 脑机接口技术的医疗器械高质量发展提供标准支撑。 脑机接口标准化建设传来新消息。 脑机接口是一种在脑与外部设备之间建立直接的通信渠道。常用于辅助、增强、修复人体的感觉—运动 功能或提升人机交互能力，目前在医学领域应用较为广泛。根据植入条件，脑机接口可分为侵入式、非 侵入式和半侵入式三种。 近年来，随着神经信号处理、生物兼容材料、高性能芯片等一系列核心技术接连突破，脑机接口得以快 速发展。与此同时，相关支持政策不断落地，标准化建设成为规范行业发展、保障产品安全有效的关键 抓手。 健康通副总裁、首席发展官张畅向21世纪经济报道记者表示，此次2项标准的立项是对工信部等七部门 此前发布的《关于推动脑机接口产业创新发展的实施意见》（简称《实施意见》）中标准体系建设相关 内容的具体落实，同时也结合行业反馈的共性难题实现了空白填补。由此，也为医疗领域开展相关研 究、临床试验等后续"专业步骤"，迈出了有章可循的关键第一步。 强化标准建设 脑 ...

Core Viewpoint - The recent approval of two medical device industry standards by the National Medical Products Administration (NMPA) marks a significant step towards the high-quality development of brain-computer interface (BCI) technologies in the medical field, providing essential support for standardization and regulation [1][2]. Group 1: Standardization and Development - The two newly established standards focus on the design and application of BCIs for medical devices, specifically addressing issues related to motor function rehabilitation and the reliability of invasive devices [7]. - The BCI market in China is projected to reach 3.2 billion yuan in 2024, with an 18.8% year-on-year growth, and is expected to grow to 5.58 billion yuan by 2027, reflecting a 20% growth rate [6]. - The establishment of these standards is a response to the challenges faced by the BCI industry, including terminology confusion, fragmented technology layout, and lack of unified regulations, which have hindered rapid development [6][7]. Group 2: Policy and Industry Resonance - Recent policies have positioned BCIs as a key future industry, with the 14th Five-Year Plan highlighting their potential as a new engine for economic growth [9]. - The NMPA has prioritized the approval of implantable BCI medical devices, expediting the market entry of innovative products [9]. - The commercial process for BCIs is expected to accelerate, with significant policy support and technological advancements driving rapid industry growth [10]. Group 3: Future Development and Market Dynamics - The future vision for the BCI industry includes cultivating globally influential leading enterprises and a number of specialized small and medium-sized enterprises by 2030 [11]. - Potential applications in the medical field are expected to expand beyond mere functional restoration to include "functional enhancement" applications, utilizing a combination of multiple devices and technologies [11].

中国省级地方两会近期陆续召开，脑机接口被写入多地政府工作报告中，围绕这一未来产业的区域竞逐 赛正加速展开。 随着创新成果不断涌现和应用探索不断深入，脑机接口市场或将迎来高速增长。据中国信通院测算， 2026年中国脑机接口产业规模预计达数十亿元，2030年的中国市场预计可达100亿元至140亿元。 面对这一未来产业，北京、上海、山东、四川等中国多地相继出台政策，加速产业布局。江西从强化科 技创新引领、推动成果转化应用、加快创新主体引育、提升产业支撑能力四个方面，部署11项重点任 务，推动脑机接口科技创新和产业创新深度融合。 江西省政协常委、农工党江西省委会专职副主委林凯表示，江西推动脑机接口技术产学研医融合起步发 展，已具备打造神经工程产业集聚区的基础条件，处于从技术突破到产业集聚的关键阶段。 尽管前景广阔，脑机接口从技术到产业仍面临诸多瓶颈。业内人士指出，对于一个从无到有的新兴行业 来说，建立标准至关重要。 中国工业和信息化部等七部门2025年联合印发的《关于推动脑机接口产业创新发展的实施意见》提出， 到2027年，中国脑机接口关键技术取得突破，初步建立先进的技术、产业、标准体系。脑机接口产品加 快应用，产业 ...

21世纪经济报道记者闫硕 脑机接口标准化建设传来新消息。 近日，国家药监局批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功能重建》《采用脑机接口技术的医疗器械侵入式设备可靠性 验证方法》等2项医疗器械行业标准制修订项目立项，为采用脑机接口技术的医疗器械高质量发展提供标准支撑。 脑机接口是一种在脑与外部设备之间建立直接的通信渠道。常用于辅助、增强、修复人体的感觉–运动功能或提升人机交互能力，目前在医学 领域应用较为广泛。根据植入条件，脑机接口可分为侵入式、非侵入式和半侵入式三种。 近年来，随着神经信号处理、生物兼容材料、高性能芯片等一系列核心技术接连突破，脑机接口得以快速发展。与此同时，相关支持政策不断 落地，标准化建设成为规范行业发展、保障产品安全有效的关键抓手。 健康通副总裁、首席发展官张畅向21世纪经济报道记者表示，此次2项标准的立项是对工信部等七部门此前发布的《关于推动脑机接口产业创 新发展的实施意见》（简称《实施意见》）中标准体系建设相关内容的具体落实，同时也结合行业反馈的共性难题实现了空白填补。由此，也 为医疗领域开展相关研究、临床试验等后续"专业步骤"，迈出了有章可循的关键第一步。 强化标 ...

Group 1 - The core point of the article is that Huali Technology (301011.SZ) has stated there is currently no cooperative relationship with Qiangnao Technology [1]

Economic Overview - As of now, 30 provinces in China have disclosed their economic performance for 2025, with 17 provinces showing GDP growth rates exceeding the national level of 5.0% [1] - Zhejiang's GDP is projected to grow by 5.5% year-on-year in 2025, maintaining a leading position in economic output [1] Artificial Intelligence Industry - The core AI industry in Zhejiang achieved revenue exceeding 600 billion yuan in the previous year, with a year-on-year growth of over 20%, leading the nation [1] - By 2025, the revenue of Zhejiang's core AI industry is expected to reach 680 billion yuan, with a growth rate of over 20% [8] Key Companies and Innovations - Strong Brain Technology secured 2 billion yuan in financing to boost the commercialization of brain-machine interfaces [5] - Yushutech reported 1 billion yuan in revenue, solidifying its position in the humanoid robot sector [5] - Deep Exploration achieved a model cost profit margin of 545%, setting a new profitability record in the AI industry [5] - Cloud Deep Robotics surpassed an annual shipment of 10,000 units, entering a new phase of scale [5] - Game Science validated the commercial value of domestic AAA games with revenue exceeding 9 billion yuan [5] - Qunkong Technology reported a net profit of 1.783 million yuan in the first half of the year, aiming to become the "global leader in spatial intelligence" [5] Traditional Manufacturing and Digital Transformation - A smart suit factory in Ningbo has improved production efficiency by 25%-30%, reducing the time to produce a suit from two weeks to three days [8] - The modern textile and apparel industry cluster in Zhejiang generated revenue of 1.13 trillion yuan from January to November 2025 [9] - The "415X" advanced manufacturing cluster in Zhejiang achieved a revenue of 8.97 trillion yuan, reflecting a year-on-year growth of 4.6% [9] Trade and Export Growth - Zhejiang's total import and export value reached 5.55 trillion yuan in 2025, with a year-on-year growth of 5.4%, surpassing the national average by 1.6 percentage points [10] - The export value was 4.19 trillion yuan, marking a growth of 7.2% [10] Ecosystem and Innovation - The innovation ecosystem in Zhejiang is characterized by a supportive environment involving government, enterprises, markets, and society, fostering a culture of collaboration and technological advancement [10]

Core Insights - The National Medical Products Administration of China has approved two industry standards for medical devices utilizing brain-computer interface (BCI) technology, indicating a push for high-quality development in this sector [1] - Analysts believe that the BCI field is entering a critical window for expansion from research validation to clinical and consumer applications, driven by recent innovative policies in medical devices [1] Industry Overview - Neuralink, founded by Elon Musk, is a leading player in the global BCI field, planning to scale up production of BCI devices and explore automated surgical solutions [3] - The global BCI market is projected to reach approximately $2.6 billion in 2024, with an annual growth rate of 11.5%, and is expected to expand to $3.3 billion by 2026 [3] - McKinsey forecasts that the BCI market in the medical sector could reach around $40 billion by 2030 and further grow to about $145 billion by 2040, with central nervous system disease treatment as a primary application area [3] Domestic Development - China's top-level policy design is providing crucial support for the development of BCI technology, with a goal to achieve breakthroughs in key technologies and establish a standard system by 2027 [4] - The number of companies in China's BCI sector has exceeded 200, with a projected industry scale of tens of billions of RMB by 2026 and an estimated 10-14 billion RMB by 2030 [4] - Rumors suggest that Qiangnao Technology is preparing for an IPO in Hong Kong, potentially becoming the first company among the "Hangzhou Six Little Dragons" to enter the capital market [4] Company Activities - In the A-share market, there are currently 50 listed companies in the BCI sector [5] - Botao Biological has invested in Haoshi Tianhui Technology, focusing on non-invasive BCI and mental health applications, aiming to accelerate clinical transformation and industrialization of innovative technologies [5] - Tianqi Co., Ltd. is entering the core BCI sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, which is crucial for domestic BCI hardware localization [6] - Innovation Medical is positioning itself in the BCI industry through its subsidiary Boling Brain Machine, which has commercialized BCI rehabilitation products [6]

Core Viewpoint - The article discusses the resurgence of the Hong Kong Stock Exchange (HKEX) as a leading platform for AI companies, highlighting a significant shift from traditional sectors to technology-driven firms, particularly in AI and semiconductor industries [6][9][12]. Group 1: IPO Trends and Market Dynamics - Wall Street's IPO market has seen a drastic decline from approximately 310 billion HKD in 2021 to just over 100 billion HKD in 2022, a drop of about 65% [6]. - In 2023, the HKEX recorded only 68 IPOs, raising around 46 billion HKD, marking the lowest level since 2013 [6]. - The first two weeks of 2026 witnessed an unprecedented AI IPO wave, with companies like Wallran Technology experiencing a 2348 times oversubscription and raising 130 billion HKD [9]. Group 2: Financial Performance of HKEX - The HKEX reported a 41% increase in major business revenue from 14,542 million HKD in 2024 to 20,438 million HKD in 2025 [10]. - The net profit attributable to shareholders rose by 45%, from 9,270 million HKD in 2024 to 13,419 million HKD in 2025 [10]. - The EBITDA for the first three quarters of 2025 reached 17,164 million HKD, a 48% increase compared to the previous year [10]. Group 3: AI Companies and Their Financial Needs - AI companies often have R&D expenditures that are several times their revenue, with companies like Zhipu spending over eight times their revenue on R&D in the first half of 2025 [11]. - Wallran Technology's revenue surged from less than 500,000 HKD in 2022 to over 300 million HKD in 2024, but its R&D expenses reached 830 million HKD, indicating a cash burn situation [11]. - The need for continuous funding is critical for AI companies, as they require a sustainable capital pool to support ongoing operations and development [12]. Group 4: Advantages of HKEX for AI Companies - The HKEX has adapted its listing rules to accommodate frontier technology companies, allowing unprofitable firms to list if they have technological barriers and top-tier capital backing [13][14]. - The minimum market capitalization requirements for companies have been lowered, benefiting many AI firms [13]. - The HKEX's approval process has been streamlined, reducing the time from 8-12 months to 4-6 months, enhancing its attractiveness for tech firms [14]. Group 5: Future Outlook and Market Sentiment - The article suggests that the HKEX will continue to attract more technology-focused companies, with several AI and semiconductor firms already in the pipeline for IPOs [16]. - The success of AI companies is paradoxical; as they succeed, they require more capital, which may lead to prolonged periods of unprofitability [17]. - Investors are betting on the potential of AI companies, despite uncertainties regarding their profitability and market sustainability [18].

2026年开年，脑机接口领域无疑是全球科技界最耀眼的明星。1月1日，马斯克在X平台的一则推文点燃 了整个行业的热情：Neuralink将在2026年启动大规模量产。很快，排队等待植入的患者已突破万人大 关。 几乎在同一时间，中国也传来振奋人心的消息：非侵入式脑机接口领域"独角兽"强脑科技（杭州"六小 龙"之一）完成约20亿元重磅融资，创下全球该领域第二大融资纪录。上海、浙江、四川等地先后明确 脑机接口医疗服务价格，将这项前沿技术正式纳入医保体系。 高位截瘫患者用意念操控轮椅自由穿梭，渐冻症患者借助合成语音重新开口说话，消费级脑机接口产品 在2026 CES展上斩获创新大奖——这些曾经只存在于科幻电影中的场景，如今正以远超预期的速度成 为现实。 然而，在这场技术狂飙的背后，一系列深刻的伦理、法律和社会问题也随之浮现。当大脑可以被"读 取"、"写入"甚至"增强"，我们是否准备好了迎接一个全新的"人机共生"时代？当脑机接口技术突破医 疗边界，开始探索认知增强、记忆备份等前沿领域，我们又该如何定义"人类"的本质？ 一、何为脑机接口？ 展望未来，随着神经科学的持续深入发展，达到更高水平的研究阶段，并借助新一代人工智能技 ...